No Data
GF SEC: Maintain the "Buy" rating for Hutchmed (China) (00013) with a fair value of 41.35 HKD.
GF SEC expects Hutchmed (China) to achieve a net income of 0.005, 0.02, and 0.074 billion USD for the years 2024-2026 respectively.
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Express News | HUTCHMED Shares Are Trading Higher After the Company Announced the Divestment of Its 45% Interest in Shanghai Hutchison Pharmaceuticals
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
6-K: Report of foreign private issuer (related to financial reporting)
HUTCHMED (China) Combination Cancer Treatment Gets NDA; Share Prices Up 5%
